Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC

Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center, discusses the implications of the phase 3 ADRIATIC trial (NCT03703297) investigating adjuvant durvalumab (Imfinzi) vs placebo in patients with limited-stage small cell lung cancer.